Besponsa®

Active substance

  inotuzumab ozogamicin

Holder

  Pfizer

Status

 Closed

Indication

  relapsed or refractory CD22-positive B-Cell precursor acute lymphoblastic leukemia (ALL) in adult patients

Public documents

 Approbation

 Information for the patient

 Informed consent

Last update

31/07/2019
Last updated on